EchoCath gains clearance for EchoFlow

Article

Ultrasound peripherals developer EchoCath has received Food and Drug Administration 510(k) clearance for EchoFlow, a blood-velocity measurement device that uses ultrasound to evaluate and quantify blood flow (SCAN 2/19/97). EchoFlow’s

Ultrasound peripherals developer EchoCath has received Food and Drug Administration 510(k) clearance for EchoFlow, a blood-velocity measurement device that uses ultrasound to evaluate and quantify blood flow (SCAN 2/19/97). EchoFlow’s applications include assessing the condition of blood vessels during and after surgery, determining proper placement of bypass grafts, and monitoring blood flow for implantable devices such as pacemakers, according to the Princeton, NJ-based firm. EchoCath will initially market EchoFlow to vascular surgeons for measuring blood-flow velocities but is also seeking corporate alliances for applications outside vascular surgery.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.